Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

119.26USD
24 Mar 2017
Change (% chg)

-- (--)
Prev Close
$119.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,542,478
52-wk High
$162.00
52-wk Low
$109.12

ALXN.O

Chart for ALXN.O

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $26,787.44
Shares Outstanding(Mil.): 224.61
Dividend: --
Yield (%): --

Financials

  ALXN.O Industry Sector
P/E (TTM): 67.77 29.17 29.94
EPS (TTM): 1.76 -- --
ROI: 3.22 13.48 13.01
ROE: 4.71 14.39 14.16

BRIEF-Alexion submits application for soliris as treatment for refractory generalized myasthenia gravis

* Alexion submits application in Japan for soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gmg) Source text for Eikon: Further company coverage:

Mar 22 2017

BRIEF-Arbutus licenses LNP delivery technology to Alexion

* Arbutus licenses LNP delivery technology to Alexion for use in single messenger RNA product candidate

Mar 16 2017

Alexion to cut 7 percent of workforce

Alexion Pharmaceuticals Inc said on Monday it has initiated a company-wide restructuring that will affect about 7 percent of its workforce.

Mar 13 2017

Alexion to cut 7 pct of workforce

March 13 Alexion Pharmaceuticals Inc said on Monday it has initiated a company-wide restructuring that will affect about 7 percent of its workforce.

Mar 13 2017

BRIEF-Alexion Pharma says initiated companywide restructuring

* Alexion Pharmaceuticals says initiated companywide restructuring

Mar 13 2017

UPDATE 3-Alexion Pharma's revenue forecast allays investor fears

* 2017 rev forecast just under estimates, but reassuring-analysts

Feb 16 2017

BRIEF-Alexion interim CEO says looking for opportunities in M&A front

* Alexion CFO says "we're preparing for potential tax reform": conf call

Feb 16 2017

Alexion Pharma revenue forecast allays fears about Soliris' future

Alexion Pharmaceuticals Inc forecast 2017 revenue that will likely quell investor concerns, as the drugmaker looks to steady the ship following the recent exits of its chief executive and chief financial officer.

Feb 16 2017

BRIEF-Alexion Pharmaceuticals posts Q4 adj. earnings $1.26/shr

* Alexion reports fourth quarter and full year 2016 results and provides financial guidance for 2017

Feb 16 2017

Alexion Pharma's revenue rises 18.5 pct

Feb 16 Alexion Pharmaceuticals Inc reported an 18.5 percent rise in fourth-quarter revenue, helped by demand for its costly rare blood disorder drug Soliris.

Feb 16 2017

More From Around the Web

Competitors

Earnings vs. Estimates